Investor Presentation First Nine Months of 2022

5 Investor presentation First nine months of 2022 Sales growth of 16% driven by both operating units Novo NordiskⓇ Reported geographic sales split for first nine months of 2022 Reported therapy area sales and growth for first nine months of 2022 DKK Insulin GLP-1 I Other diabetes billion Obesity care Rare disease Growth at CER North America Operations DKK billion Growth at CER International Operations 150 70 0 22% 11% 16% 44% -11% 75% 2% 50 60 50 40 41 30 20 20 10 International Operations 100 11% 13% -7% ΙΟ NAO 22% 50 55% -20% 4% -5% 73% ΙΟ 22% ΙΟ NAO -3% 39% 77% NAO 0 0 NAO ΙΟ EMEA China ROW Total 1 GLP-1 Insulin Obesity care Rare disease 1 'Other diabetes' is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations Note: Unless otherwise specified, sales growth rates are at CER

View entire presentation